These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 28766389)

  • 21. Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases.
    Jurczak W; Cohen S; Illidge TM; Silva AD; Amersdorffer J
    Future Oncol; 2019 Dec; 15(36):4223-4234. PubMed ID: 31718287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.
    Bishton M; Marshall S; Harchowal J; Salles G; Golfier C; Tucci A; Fernández AR; Sanchez Blanco JJ; Bocchia M; Kim S; Lee YN; Zinzani PL
    Hematol Oncol; 2022 Aug; 40(3):370-380. PubMed ID: 35168291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.
    Cohen S; Emery P; Greenwald M; Yin D; Becker JC; Melia LA; Li R; Gumbiner B; Thomas D; Spencer-Green G; Meng X
    Br J Clin Pharmacol; 2016 Jul; 82(1):129-38. PubMed ID: 26909489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.
    Yoo DH; Suh CH; Shim SC; Jeka S; Cons-Molina FF; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kwon TS; Park W
    Ann Rheum Dis; 2017 Mar; 76(3):566-570. PubMed ID: 27624791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
    Ogura M; Coiffier B; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
    Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
    Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
    Smolen JS; Cohen SB; Tony HP; Scheinberg M; Kivitz A; Balanescu A; Gomez-Reino J; Cen L; Poetzl J; Shisha T; Kollins D
    Rheumatology (Oxford); 2021 Jan; 60(1):256-262. PubMed ID: 32699904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study.
    Della-Torre E; Lanzillotta M; Campochiaro C; Di-Colo G; Mancuso G; Capurso G; Falconi M; Dagna L
    Eur J Intern Med; 2021 Feb; 84():63-67. PubMed ID: 33386207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial.
    den Broeder AA; Verhoef LM; Fransen J; Thurlings R; van den Bemt BJF; Teerenstra S; Boers N; den Broeder N; van den Hoogen FHJ
    Trials; 2017 Aug; 18(1):403. PubMed ID: 28854956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
    Rioufol C; Salles G
    Expert Rev Anticancer Ther; 2015 May; 15(5):569-78. PubMed ID: 25818308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.
    Lee KH; Lee J; Bae JS; Kim YJ; Kang HA; Kim SH; Lee SJ; Lim KJ; Lee JW; Jung SK; Chang SJ
    MAbs; 2018 Apr; 10(3):380-396. PubMed ID: 29469653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-Use Stability of the Rituximab Biosimilar CT-P10 (Truxima
    Kim SJ; Kim KW; Shin YK; Kwon JW; Kang HY; Park YA; Shin JY; Kim SY; Han WY
    BioDrugs; 2019 Apr; 33(2):221-228. PubMed ID: 30747341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab biosimilars for lymphoma in Europe.
    Jurczak W; Długosz Danecka M; Buske C
    Expert Opin Biol Ther; 2019 Oct; 19(10):1045-1056. PubMed ID: 31512535
    [No Abstract]   [Full Text] [Related]  

  • 34. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
    Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
    BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
    Kim WS; Coiffier B; Kwon HC; Kim S
    Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The retrospective evaluation of efficacy and safety data after switching from originator rituximab to biosimilar rituximab (CT-P10) in patients diagnosed with systemic lupus erythematosus: a single-center experience.
    Ekin A; Mısırcı S; Coşkun BN; Yağız B; Dalkılıç E; Pehlivan Y
    Eur Rev Med Pharmacol Sci; 2024 May; 28(10):3513-3522. PubMed ID: 38856126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study.
    McBride A; Daniel S; Driessen MT; Szende A; Choudhry A; Tian M; Ariely R; Thompson S
    Leuk Res; 2021 Dec; 111():106671. PubMed ID: 34530254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.
    Smolewski P; Robak T
    Expert Opin Drug Discov; 2015 Jul; 10(7):791-808. PubMed ID: 26083358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.
    Buske C; Ogura M; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):5-16. PubMed ID: 28482702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.